Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Press release - No. 10 / 2018
Zealand Pharma will attend the Kempen Life Science Conference on April 18, 2018 in Amsterdam
Copenhagen, April 12, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will attend the Kempen Life Science Conference in Amsterdam on April 18, 2018.
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, e-mail: [email protected]
Mats Blom, Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
